Jade Biosciences, Inc. (NASDAQ:JBIO) Receives Average Recommendation of "Moderate Buy" from Analysts

Key Points

• Analyst sentiment is moderately bullish: Ten analysts collectively rate Jade Biosciences “Moderate Buy,” with six buys, two strong buys, one hold and one sell. The average 12-month price target is $51.75.
• Recent analysts have raised their targets, including BTIG Research to $77 and HC Wainwright to $55, although Wall Street Zen downgraded the stock to “strong sell.”
• Jade Biosciences reported a quarterly loss of $0.76 per share, missing expectations of a $0.66 loss, and analysts expect a full-year loss of approximately $2.84 per share. The clinical-stage biotech has no marketed products and is developing antibody-based treatments for autoimmune and inflammatory diseases.

Shares of Jade Biosciences, Inc. (NASDAQ:JBIO - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the ten ratings firms that are presently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, six have issued a buy rating and two have given a strong buy rating to the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $51.75.

A number of analysts recently issued reports on the company. HC Wainwright lifted their target price on Jade Biosciences from $45.00 to $55.00 and gave the company a "buy" rating in a research report on Monday, June 1st. BTIG Research increased their price target on Jade Biosciences from $74.00 to $77.00 and gave the company a "buy" rating in a research report on Monday, August 10th. Wall Street Zen downgraded Jade Biosciences from a "sell" rating to a "strong sell" rating in a research note on Saturday, September 12th. Guggenheim reaffirmed a "buy" rating and set a $47.00 price target on shares of Jade Biosciences in a research report on Tuesday, June 2nd. Finally, UBS Group initiated coverage on Jade Biosciences in a research note on Monday, June 15th. They set a "buy" rating and a $45.00 price objective on the stock.

Jade Biosciences Trading Up 0.1%

Jade Biosciences stock opened at $14.73 on Friday. Jade Biosciences has a 1-year low of $7.69 and a 1-year high of $28.00. The company has a fifty day simple moving average of $20.17 and a 200 day simple moving average of $19.74. The company has a market cap of $936.83 million, a P/E ratio of -7.67 and a beta of 1.45.

Jade Biosciences (NASDAQ:JBIO - Get Free Report) last issued its quarterly earnings results on Monday, August 10th. The company reported ($0.76) EPS for the quarter, missing the consensus estimate of ($0.66) by ($0.10). On average, equities research analysts forecast that Jade Biosciences will post -2.84 EPS for the current year.

Institutional Trading of Jade Biosciences

Several institutional investors and hedge funds have recently added to or reduced their stakes in JBIO. Renaissance Technologies LLC grew its position in shares of Jade Biosciences by 94.0% in the 1st quarter. Renaissance Technologies LLC now owns 135,039 shares of the company's stock valued at $1,897,000 after acquiring an additional 65,438 shares during the period. Stempoint Capital LP bought a new stake in shares of Jade Biosciences in the 1st quarter valued at about $2,164,000. Janus Henderson Group PLC bought a new stake in shares of Jade Biosciences in the 1st quarter valued at about $43,557,000. Baker BROS. Advisors LP acquired a new stake in Jade Biosciences in the 4th quarter valued at about $25,323,000. Finally, Maven Securities LTD acquired a new stake in Jade Biosciences in the 2nd quarter valued at about $1,111,000.

Jade Biosciences Company Profile

Jade Biosciences, Inc NASDAQ: JBIO is a clinical-stage biotechnology company focused on developing medicines for autoimmune and inflammatory diseases. The company uses antibody-based drug discovery and development approaches to pursue therapies intended to address significant unmet medical needs.

Jade Biosciences is advancing a pipeline of investigational programs and does not currently have commercially marketed products. Its work is centered on identifying and developing targeted therapies that may modulate biological pathways involved in autoimmune disease.

The company's activities primarily consist of research, preclinical development and clinical evaluation of its drug candidates.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.